Objective The aim of the study was to comprehensively summarize the survival outcomes
and complications of Impella 5.0 (Abiomed Inc, Danvers, MA USA) use in patients with …

The adverse outcomes of a ventricular heart failure (left, right or biventricular) caused by
cardiogenic shock are aggravated by lung oedema and organ mal perfusion. Despite …

Cardiogenic shock from biventricular failure that requires acute mechanical circulatory
support carries high 30 day mortality. Acute mechanical circulatory support can serve as …

Background—Acute cardiogenic shock after myocardial infarction is associated with high in-
hospital mortality attributable to persisting low-cardiac output. The Impella–EUROSHOCK …

Despite growing utilization of large microaxial pump, ie, Impella 5.0 or 5.5 (Abiomed Inc.,
Danvers, MA, USA)(Impella 5+) for cardiogenic shock (CS) patients, adverse events …

OBJECTIVES Postcardiotomy cardiogenic shock (PCCS) is associated with high mortality
rates of 50–80%. Although veno-arterial extracorporeal membrane oxygenation has been …

Introduction Cardiogenic shock (CS) is a life-threatening condition and mechanical
circulatory support (MCS) might exert a relevant impact on its clinical course. Among MCS …

The Impella device is a catheter-based miniaturized ventricular assist device. Using a
retrograde femoral artery access, it is placed in the left ventricle across the aortic valve. The …

The Impella 5.0 microaxial pump is a miniaturized left ventricular assist device commonly
used for circulatory support in acute cardiogenic shock. The catheter-based pump is …

Aims We sought to investigate the outcomes of heart transplant patients supported with
Impella 5.5 temporary mechanical circulatory support. Methods and results Patient …